GC Biopharma (006280) stock
KOSPI · Pharmaceuticals
As of Nov 16, 2:16 PM KST
Events and reference metrics · 1
- Market cap
- KRW 1.6 trillion
- As of Nov 16, 2026
- P/E
- -31.19x
- Trailing twelve months
- P/B
- 1.27x
- Latest reported equity
- P/S
- 0.79x
- Trailing twelve months
- ROE
- -4.1%
- Trailing twelve months
- Dividend yield
- 1.13%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 1.6 trillion
- As of Nov 16, 2026
- P/E
- -31.19x
- Trailing twelve months
- P/B
- 1.27x
- Latest reported equity
- P/S
- 0.79x
- Trailing twelve months
- ROE
- -4.1%
- Trailing twelve months
- Dividend yield
- 1.13%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-31.19x
Net loss — not comparable
P/B
1.27x
P/S
0.79x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 4,270
Earnings per share
BPS
KRW 105,137
Book value per share
ROE
-4.1%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 4,270 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 105,137 of net assets.
- ROE — shareholder equity shrank by 4.1% over a year.
Dividends
1 observed in the last year · Record dates: Mar
Yield
1.13%
Yield uses dividends observed over the last year (by record date).
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 421.2 billion | KRW 1.7 billion | KRW 1 billion | -15.8% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 435.5 billion | KRW 11.7 billion | KRW 20.1 billion | +13.5% |
| Q4 2025Consolidated · Filed Mar 18, 2026 | KRW 497.8 billion | KRW 4.6 billion | -KRW 102.8 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 609.5 billion | KRW 29.2 billion | KRW 18.1 billion | +31.1% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 500.3 billion | KRW 27.4 billion | KRW 32.7 billion | +19.9% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 383.8 billion | KRW 8 billion | KRW 22.3 billion | +7.6% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 18, 2026 | KRW 2 trillion | KRW 69.1 billion | -KRW 29.7 billion | — |
| FY2024Consolidated · Filed Mar 18, 2025 | KRW 1.7 trillion | KRW 32.1 billion | -KRW 42.6 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 8.94%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 360 million
- Previous 20-day average 15.67%
- Net short position
- 30,087 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 423,334 shares
- As of Nov 13, 2026 · 3.62% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 8.94% | KRW 360 million |
| Nov 12, 2026 | 17.37% | KRW 1.03 billion |
| Nov 11, 2026 | 7.47% | KRW 290 million |
| Nov 10, 2026 | 7.84% | KRW 390 million |
| Nov 9, 2026 | 11.60% | KRW 420 million |
| Nov 6, 2026 | 9.81% | KRW 850 million |
| Nov 5, 2026 | 4.49% | KRW 550 million |
| Nov 4, 2026 | 26.24% | KRW 1.9 billion |
| Nov 3, 2026 | 12.32% | KRW 1.39 billion |
| Nov 2, 2026 | 13.96% | KRW 770 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Single Sales or Supply ContractNov 2, 2026 · Supply ContractEnglish
- [Amended] Single Sales or Supply ContractNov 2, 2026 · Supply ContractEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)Nov 2, 2026 · Preliminary EarningsEnglish
- Material Management Information for Investment Decisions(Korean)Oct 30, 2026 · Material Management Information
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 7, 2026 · Insider Ownership Report
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)Jul 31, 2026 · Preliminary Earnings
- New Facility Investment(Korean)Jul 16, 2026 · Investment
- [Amended] Decision on Transfer of Shares in Another Company(Korean)Jul 10, 2026 · Investment
Filings with a published English version open in English; the rest link to the Korean original.
GC Biopharma (006280) stock information
KOSPI
GC Biopharma (006280) is listed on KOSPI. Its market capitalization is about KRW 1.6 trillion. On trailing-twelve-month earnings the P/E ratio is -31.19, and the P/B ratio is 1.27. Return on equity is -4.1%. These figures are computed in-house from official filings and are reference information only.
GC Biopharma — frequently asked questions
- What is the P/E ratio of GC Biopharma (006280)?
- On a trailing-twelve-month basis, 006280 trades at a P/E ratio of -31.19. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of GC Biopharma?
- 006280 has a market capitalization of about KRW 1.6 trillion. The figure moves with the share price and is refreshed each trading day.
- Does GC Biopharma pay a dividend?
- 006280 has a dividend yield of about 1.13%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.